2010
Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option?
Grotz TE, Nagorney D, Donohue J, Que F, Kendrick M, Farnell M, Harmsen S, Mulligan D, Nguyen J, Rosen C, Reid-Lombardo K. Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option? Hepato Pancreato Biliary 2010, 12: 546-553. PMID: 20887322, PMCID: PMC2997660, DOI: 10.1111/j.1477-2574.2010.00213.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChi-Square DistributionDisease-Free SurvivalFemaleHemangioendothelioma, EpithelioidHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsLiver TransplantationMaleMiddle AgedPalliative CareProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsHepatic epithelioid haemangioendotheliomaOrthotopic liver transplantationDisease-free survivalLiver resectionOverall survivalPrognostic factorsFavorable prognostic factorUnfavourable prognostic factorOnly treatment optionUnpredictable clinical behaviorRare vascular neoplasmResectable diseaseUnresectable diseaseEpithelioid haemangioendotheliomaLiver transplantationFavorable OSFemale predominanceMedian ageSurgical treatmentMultifocal diseaseRetrospective reviewTreatment optionsLarge tumorsClinical behaviorMayo Clinic
2004
Hepatitis C Virus Infection with Hepatocellular Carcinoma: Not A Controversial Indication for Liver Transplantation
Rodriguez-Luna H, Balan V, Sharma P, Byrne T, Mulligan D, Rakela J, Vargas HE. Hepatitis C Virus Infection with Hepatocellular Carcinoma: Not A Controversial Indication for Liver Transplantation. Transplantation 2004, 78: 580-583. PMID: 15446318, DOI: 10.1097/01.tp.0000129797.30999.69.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionC virus infectionHepatocellular carcinomaHCV/Liver transplantationVirus infectionChronic hepatitis C virus (HCV) infectionSurvival rateChronic HCV infectionOrthotopic liver transplantationOutcomes of patientsOrgan Sharing dataHCC recurrence rateOverall survival rateLower survival rateHCV groupLT patientsHCV infectionHCC recurrencePatient survivalRecurrence rateUnited NetworkMean agePotential contraindicationsHCC groupHepatitis C Virus Quasi-Species Dynamics Predict Progression of Fibrosis after Liver Transplantation
Arenas JI, Gallegos-Orozco JF, Laskus T, Wilkinson J, Khatib A, Fasola C, Adair D, Radkowski M, Kibler KV, Nowicki M, Douglas D, Williams J, Netto G, Mulligan D, Klintmalm G, Rakela J, Vargas HE. Hepatitis C Virus Quasi-Species Dynamics Predict Progression of Fibrosis after Liver Transplantation. The Journal Of Infectious Diseases 2004, 189: 2037-2046. PMID: 15143471, DOI: 10.1086/386338.Peer-Reviewed Original ResearchMeSH Keywords5' Untranslated RegionsDisease ProgressionElectrophoresis, Polyacrylamide GelFemaleGenetic VariationHepacivirusHepatitis C, ChronicHumansLiver CirrhosisLiver TransplantationMaleMiddle AgedPhylogenyPolymorphism, Single-Stranded ConformationalReverse Transcriptase Polymerase Chain ReactionRNA, ViralViral Envelope ProteinsConceptsOrthotopic liver transplantationHepatitis C virusLiver transplantationGroup 1Quasi speciesSeverity of recurrenceGroup 1 patientsGroup 2 patientsE2 regionProgression of fibrosisPost-OLT periodCourse of infectionHeteroduplex mobility assayHCV complexityHCV infectionC virusGroup 2PatientsTransplantationSingle-strand conformational polymorphismLiver samplesInfectionWeeksQuasi-species dynamicsYearsTreatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1
Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1. Transplantation 2004, 77: 190-194. PMID: 14742979, DOI: 10.1097/01.tp.0000100481.14514.bb.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsDrug Therapy, CombinationFemaleHepacivirusHepatitis CHumansImmunosuppressive AgentsInterferon alpha-2Interferon-alphaLiver Function TestsLiver TransplantationMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRecurrenceReverse Transcriptase Polymerase Chain ReactionRibavirinRNA, ViralTime FactorsTreatment OutcomeConceptsOrthotopic liver transplantationEnd of treatmentHCV recurrenceLiver transplantationPEG-IFNHepatitis C virus recurrenceRecurrent hepatitis C infectionDiscontinuation of therapyNecro-inflammatory scoreUndetectable viral loadHepatitis C infectionResponse 6 monthsBone marrow toxicityReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionHistologic benefitRecurrent HCVVirologic clearanceC infectionVirologic responseVirus recurrenceAggressive managementCombination regimenViral clearanceViral response
2003
Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area
Blair JE, Douglas DD, Mulligan DC. Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transplant Infectious Disease 2003, 5: 3-8. PMID: 12791068, DOI: 10.1034/j.1399-3062.2003.00005.x.Peer-Reviewed Original ResearchConceptsOrthotopic liver transplantationLiver transplantationPositive serologic resultsCoccidioidal infectionSerologic resultsEndemic areasEnd-stage liver diseaseReactivation of coccidioidomycosisRisk of coccidioidomycosisLiver transplant candidatesEndemic fungal infectionProphylactic fluconazoleTransplant recipientsUniversal prophylaxisDisseminated diseaseTransplant candidatesImmunocompromised hostLiver diseaseRecurrent infectionsClose surveillancePositive historyPatientsProphylaxisTransplantationHigh mortality
2002
Thrombendvenectomy for Organized Portal Vein Thrombosis at the Time of Liver Transplantation
Molmenti EP, Roodhouse TW, Molmenti H, Jaiswal K, Jung G, Marubashi S, Sanchez EQ, Gogel B, Levy MF, Goldstein RM, Fasola CG, Elliott EE, Bursac N, Mulligan D, Gonwa TA, Klintmalm GB. Thrombendvenectomy for Organized Portal Vein Thrombosis at the Time of Liver Transplantation. Annals Of Surgery 2002, 235: 292-296. PMID: 11807371, PMCID: PMC1422428, DOI: 10.1097/00000658-200202000-00019.Peer-Reviewed Original ResearchConceptsPortal vein thrombosisGraft survival ratesTime of transplantationLiver transplantationVein thrombosisMale patientsFemale patientsLiver diseasePortal veinControl groupSurvival rateEnd-stage liver diseaseOrthotopic liver transplantOrthotopic liver transplantationFirst postoperative dayIntensive care unitLength of stayCryptogenic cirrhosisDaily aspirinPVT groupPVT patientsTacrolimus immunosuppressionLiver transplantTransplant recipientsPostoperative day
2000
The effect of orthotopic liver transplantation on the QTc interval in patients with end-stage liver disease
Carey E, Mulligan D, Balan V, Harrison M, Rakela J, Douglas D. The effect of orthotopic liver transplantation on the QTc interval in patients with end-stage liver disease. The American Journal Of Gastroenterology 2000, 95: 2507. DOI: 10.1111/j.1572-0241.2000.02690.x.Peer-Reviewed Original ResearchEnd-stage liver diseaseOrthotopic liver transplantationLiver transplantationLiver diseaseQTc intervalPatientsTransplantationDisease
1998
A Prospective Longitudinal Analysis of ATGAM Induction Versus Mycophenolate Mofetil Maintenance Immunosuppression for Orthotopic Liver Transplantation
Mulligan D, Bush W, Shiffrin F, Cowan R, Penko M, Sterling R, Post A, Schulak J. A Prospective Longitudinal Analysis of ATGAM Induction Versus Mycophenolate Mofetil Maintenance Immunosuppression for Orthotopic Liver Transplantation. Transplantation 1998, 66: s51. DOI: 10.1097/00007890-199810270-00233.Peer-Reviewed Original ResearchRESOLUTION OF SPUR CELL ANEMIA WITH LIVER TRANSPLANTATION
Chitale AA, Sterling RK, Post AB, Silver BJ, Mulligan DC, Schulak JA. RESOLUTION OF SPUR CELL ANEMIA WITH LIVER TRANSPLANTATION. Transplantation 1998, 65: 993-995. PMID: 9565106, DOI: 10.1097/00007890-199804150-00021.Peer-Reviewed Original ResearchConceptsSpur cell anemiaCell anemiaOrthotopic liver transplantationLiver transplantationYounger patientsDiseased liverHemolytic anemiaSpur cellsSpontaneous resolutionAlcohol abuseUnusual caseAnemiaIncreased percentageCirrhosisLiverErythrocytesCell surfacePatientsTransplantationNumerous spiculesHemochromatosis